$2.01
+0.10 (+5.24%)
Open$1.94
Previous Close$1.91
Day High$2.04
Day Low$1.93
52W High$4.53
52W Low$1.79
Volume—
Avg Volume220.7K
Market Cap60.68M
P/E Ratio0.54
EPS$2.91
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+543.3% upside
Current
$2.01
$2.01
Target
$12.93
$12.93
$7.67
$12.93 avg
$16.62
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 68.45M | 72.68M | 15.02M |
| Net Income | 7.37M | 7.04M | -500,427 |
| Profit Margin | 10.8% | 10.2% | -3.3% |
| EBITDA | -42,019,307 | -42,385,157 | -867,054 |
| Free Cash Flow | — | — | -309,659 |
| Rev Growth | -5.8% | -5.8% | +23.3% |
| Debt/Equity | 1.19 | 1.19 | 0.77 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |